Market Trends of Ulcerative Colitis Industry
Immunosuppressants Under the Drug Type Segment is Expected to Have the Largest Growth Over the Forecast Period
Immunomodulators, often called immunosuppressants, are a type of medication used in ulcerative colitis to weaken or modulate the activity of the immune system. The research studies for new immunosuppressants for ulcerative colitis, a type of inflammatory bowel disease, along with the increased focus of key market players in developing these drugs, are expected to have the largest segment growth in the market over the forecast period.
According to the study report published by the Springer Drugs journal in March 2023, novel JAK inhibitors, one of the immunomodulating agents with a more focused effect on JAK-1, have shown promise in the treatment of ulcerative colitis, potentially providing a safer and more successful therapeutic option for patients, particularly those who have previously not responded to traditional treatment options. These advanced agents increase the demand for immunosuppressants with their effectiveness in treating ulcerative colitis, which likely propels the segment's growth over the study period.
Immunosuppressants, such as tacrolimus and azathioprine, are commonly used for ulcerative colitis. As per the study report published by Cureus in May 2022, azathioprine was an effective and affordable medication for ulcerative colitis patients who desired to maintain remission for an extended period. Due to this cost-effective treatment option, the market is expected to grow most over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to lead the ulcerative colitis market, owing to the presence of key players and the increasing prevalence of ulcerative colitis in the region, along with the continuing funding for developing innovative solutions for treating ulcerative colitis.
The high focus on research activities by the market players is also contributing to the market's growth. For instance, in August 2022, Teva Pharmaceutical Industries initiated a phase II clinical trial to assess the efficacy and safety of TEV-48574 for Ulcerative Colitis. Thus, the new research studies help increase companies' product portfolio, which is expected to drive market growth over the forecast period in the region.
Additionally, approvals from regulatory authorities such as the United States Food and Drug Administration, Health Canada, and others are also propelling the market's growth. For instance, in May 2021, Bristol Myers Squibb received approval from the United States Food and Drug Administration (FDA) for Zeposia (ozanimod) in the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). Thus, owing to the abovementioned factors, it is expected to have increased demand for various ulcerative colitis treatment products in the region, which will likely propel the market growth over the forecast period.
